<DOC>
	<DOCNO>NCT01921491</DOCNO>
	<brief_summary>The purpose study determine whether dehydrate human amnion/chorion membrane ( dHACM ) effective another commercially available product conservative measure alone use treat diabetic foot ulcer ( DFUs ) .</brief_summary>
	<brief_title>DHACM vs Other Commercially Available Treatments</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1 . Patients age 18 old . 2 . Patient willing provide inform consent willing participate procedure follow evaluation necessary complete study . 3 . Patient 's ulcer must diabetic origin large 1 cm2 . Note : Debridement do prior randomization . Subject 's informed consent participate study , must obtain prior proceed sharp debridement . 4 . Patients Type 1 Type 2 diabetes ( criterion diagnosis diabetes mellitus per ADA ) . 5 . Ulcer must present minimum four week enrollment/ randomization , documented failure conventional ulcer therapy heal wound . A two week runin period precede enrollment/ randomization trial document indolent nature wound select . 6 . Additional wound may present within 3 cm study wound . 7 . Wound must present anatomically foot define begin malleoli ankle neuropathic origin . 8 . Patient 's ulcer must exhibit clinical sign infection . 9 . Serum Creatinine le 3.0mg/dl within last six month . 10 . HbA1c le equal 12 % within last 90 day . 11 . Patient adequate circulation affect extremity , demonstrate one follow within past 60 day : 1 . Dorsum transcutaneous oxygen test ( TcPO2 ) result ≥30mmHg , OR 2 . ABIs result ≥0.7 ≤1.2 , OR 3 . Doppler arterial waveform , triphasic biphasic ankle affect leg . 1 . Patients present ulcer probe tendon , muscle , capsule bone ( UT Grade IIIAD ) . A positive probetobone confirm bone joint felt sterile , ophthalmological probe . 2 . Patients whose index diabetic foot ulcer great 25 cm2 . 3 . Patients consider reasonable metabolic control , confirm HbA1c great 12 % within previous 90 day . 4 . Patients whose serum creatinine level 3.0mg/dl great within last six month . 5 . Patients known history poor compliance medical treatment . 6 . Patients previously randomize study , presently participate another clinical trial . 7 . Patients currently receive radiation therapy chemotherapy . 8 . Patients know suspected local skin malignancy index diabetic ulcer . 9 . Patients diagnose autoimmune connective tissue disease . 10 . Nonrevascularizable surgical site . 11 . Active infection site . 12 . Any pathology would limit blood supply compromise healing . 13 . Patients receive biomedical topical growth factor wound within previous 30 day . 14 . Patients pregnant breast feed . 15 . Patients take medication consider immune system modulators could affect graft incorporation . 16 . Known allergy Gentamicin Streptomycin , bovine collagen . 17 . Patients know hypersensitivity component treatment use trial . 18 . Wounds great one year duration without intermittent healing . 19 . Wounds improve great 20 % first two week ( runin period ) trial use standard care dress camboot . 20 . Patients take Cox2 inhibitor . 21 . Planned use Dakin 's solution , Mafenide Acetate , Scarlet Red Dressing , Tincoban , Zinc Sulfate , Povidone Iodine solution , Mafenide Acetate , Polymyxin/Nystatin Chlorhexidine trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>